Articles: sars-cov-2.
-
Randomized Controlled Trial
Case control study of access to medications during COVID-19 and longitudinal impact on health outcomes for primary care patients managing multiple chronic conditions.
During coronavirus disease 2019 (COVID-19), people managing multiple chronic conditions (MCCs) experienced barriers to obtaining needed medications. The purposes of this paper are to (i) determine risk factors for difficulty obtaining medications during COVID-19, (ii) document reasons for the difficulty, and (iii) evaluate the impact on later physical and mental health outcomes. ⋯ People with socioeconomic disadvantages experienced a disproportionate impact of difficulty obtaining medications and poorer health outcomes due to COVID-19. They may be at greater risk in the event of future pandemics and other societal disruptions.
-
Randomized Controlled Trial
Therapeutic BCG vaccine protects against long COVID: The BATTLE randomized clinical trial.
Bacillus Calmette-Guérin (BCG) injected during the COVID-19 convalescence period was safe and enhanced recovery from anosmia and dysgeusia in the acute phase. ⋯ Not tested for previous mycobacterial exposure; loss to follow-up, particularly at 12 months.
-
Journal of critical care · Dec 2024
Randomized Controlled Trial Multicenter StudyAntisense therapy to block the Kallikrein-kinin pathway in COVID-19: The ASKCOV randomized controlled trial.
To assess the effect of antisense therapy to block kallikrein-kinin pathway in COVID-19 patients. ⋯ NCT04549922.
-
Randomized Controlled Trial
Utilizing press needle acupuncture to treat mild-to-moderate COVID-19: A single-blind, randomized controlled trial.
In China, acupuncture has been employed as an adjunctive therapy for coronavirus disease 2019 (COVID-19). Press needle acupuncture is a special type of acupuncture that provides prolonged stimulation to acupuncture points and simultaneously reduces the pain associated with traditional acupuncture. This study assessed the effectiveness of integrating press needles alongside pharmacologic treatment in patients with mild-to-moderate COVID-19. ⋯ This study suggests that utilizing press needle acupuncture as an adjunct to pharmacologic treatment can be effective in patients with mild-to-moderate COVID-19 symptoms.
-
Randomized Controlled Trial
In adults with postacute sequelae of COVID-19, nirmatrelvir-ritonavir did not improve symptoms at 10 wk.
Geng LN, Bonilla H, Hedlin H, et al. Nirmatrelvir-ritonavir and symptoms in adults with postacute sequelae of SARS-CoV-2 infection: the STOP-PASC randomized clinical trial. JAMA Intern Med. 2024;184:1024-1034. 38848477.